Armistice Capital LLC Acquires 25,000 Shares of Evaxion Biotech A/S (NASDAQ:EVAX)

Armistice Capital LLC boosted its holdings in shares of Evaxion Biotech A/S (NASDAQ:EVAX) by 6.8% in the second quarter, Holdings Channel reports. The firm owned 392,000 shares of the company’s stock after purchasing an additional 25,000 shares during the quarter. Armistice Capital LLC owned about 0.07% of Evaxion Biotech A/S worth $1,137,000 at the end of the most recent reporting period.

Separately, LM Advisors LLC acquired a new position in shares of Evaxion Biotech A/S in the 4th quarter worth approximately $231,000. 11.04% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price target on shares of Evaxion Biotech A/S in a research note on Thursday.

Evaxion Biotech A/S Stock Up 8.1 %

EVAX opened at $3.06 on Friday. The firm has a market cap of $17.07 million, a price-to-earnings ratio of -0.71 and a beta of -0.27. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 2.80. The firm’s 50-day simple moving average is $2.99 and its 200-day simple moving average is $3.31. Evaxion Biotech A/S has a twelve month low of $2.26 and a twelve month high of $13.61.

Evaxion Biotech A/S (NASDAQ:EVAX) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.14). The business had revenue of $0.15 million for the quarter, compared to analysts’ expectations of $0.10 million. During the same quarter last year, the company earned ($2.10) earnings per share. Equities research analysts anticipate that Evaxion Biotech A/S will post -0.24 EPS for the current fiscal year.

Evaxion Biotech A/S Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers.